Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) COO Nathan J. Dowden sold 847 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $16.00, for a total transaction of $13,552.00. Following the completion of the transaction, the chief operating officer now directly owns 125,149 shares in the company, valued at $2,002,384. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Entrada Therapeutics Stock Performance
Shares of Entrada Therapeutics stock opened at $15.98 on Tuesday. Entrada Therapeutics, Inc. has a 1 year low of $10.75 and a 1 year high of $18.17. The company has a market capitalization of $594.46 million, a P/E ratio of 25.37 and a beta of -0.24. The company's fifty day moving average is $15.72 and its two-hundred day moving average is $14.86.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.90. The business had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. As a group, equities analysts expect that Entrada Therapeutics, Inc. will post 0.68 earnings per share for the current year.
Institutional Trading of Entrada Therapeutics
[Urgent!] Web3 Could Send One Crypto Soaring
From Crypto 101 Media | Ad
Venture Capital corporations and blockchain funds are pouring money into Web3 gaming.
And there's one little-known crypto coin that's poised for RAPID growth as we see Web3 expand over the next few years.
Click here to review my research and unique strategy to score potential profits from this under-the-
Several hedge funds and other institutional investors have recently made changes to their positions in TRDA. Allspring Global Investments Holdings LLC boosted its holdings in shares of Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company's stock valued at $209,000 after acquiring an additional 11,965 shares in the last quarter. New York State Teachers Retirement System purchased a new stake in shares of Entrada Therapeutics in the first quarter valued at about $27,000. Vanguard Group Inc. boosted its holdings in shares of Entrada Therapeutics by 1.3% in the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company's stock valued at $15,288,000 after acquiring an additional 13,742 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics in the first quarter valued at about $79,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Entrada Therapeutics by 13.4% in the second quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company's stock valued at $1,787,000 after acquiring an additional 14,838 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on TRDA shares. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 14th. Oppenheimer reissued an "outperform" rating and set a $25.00 price objective on shares of Entrada Therapeutics in a research report on Monday, August 26th.
Get Our Latest Research Report on Entrada Therapeutics
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
